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There appears to be an increased incidence of
PCa in this population. These tumors can be
approached in the same way as in the general
population, and due to the potentially worse
prognosis related to immunosuppression, a more
regular follow-up is required in this specific
population.
• One patient presented with osseous metastases and was managed with





We conducted a retrospective review of data from
1835 male patients who underwent renal
transplantation between January 1987 and
December 2016. Recipients presenting PCa were
evaluated regarding the type of histology, age,
posttransplant duration, immunosuppressive
regimens, allograft functional status and PSA
value. We retrospectively assessed the stage of
the disease, treatment performed and consequent
oncologic outcome. Patients with a history of pre-
existing cancers were excluded.
Immunosuppressed organ transplant patients
have an elevated risk of malignancies. In this
study we aim to determine the incidence of
prostate cancer (PCa) in renal transplant
recipients, as well as to evaluate their monitoring,
treatment and oncological outcomes.
Table 2 Clinicopathological characteristics of PCa patients
























49 64 7.4 192 pT2cNx 7 (3+4) RP Failed Alive
66 67 16 17 pT3bN0 9 (4+5) RP Good Alive
69 69 16 2 pT2cNo 7 (4+3) RP Failed Deceased
62 71 6.15 100 n/a n/a RT Failed Alive 
53 53 1 2 pT2aNx 6 (3+3) RP Good Alive
34 54 6.1 235 pT3aN0 6 (3+3) RP Good Alive
44 56 9.2 145 pT3aNa 7 (3+4) RP Good Alive
63 65 7.7 25 pT3aNx 7 (3+4) RT Good Alive
42 53 35.9 108 n/a n/a RP Failed Alive
64 64 5.4 4 pT2cN0 7 (3+4) RT Failed Alive
58 65 5.3 84 n/a n/a RT Good Alive
58 68 11.7 140 n/a n/a AS Good Alive
43 68 1 181 n/a n/a RP Failed Deceased
48 62 8.6 166 pT2cN0 7 (4+3) RP Good Alive
64 65 3.3 8 pT2cNa 7 (3+4) RP Good Alive
61 58 4.2 87 pT3aN0 7 (3+4) RP Good Alive
56 58 18.2 24 pT2cN0 7 (3+4) AS Good Alive
57 66 1.1 94 n/a n/a RP Good Alive
50 73 7.9 285 pT2cN0 7 (3+4) RP Failed Deceased
38 59 5 258 pT3aN0 7 (3+4) RT Failed Alive
49 65 18 191 n/a n/a RP Failed Deceased
63 63 1 3 n/a n/a WD Good Alive
29 50 10 132 pT3aN0 7 (3+4) AS Failed Alive
54 68 9.5 167 pT3aNx 7 (3+4) RP Failed Deceased
42 58 12.4 190 pT2cN0 6 (3+3) RP Good Alive
64 69 5.6 61 pT3aN0 7 (4+3) RP Good Alive
55 57 4.2 30 pT2cN0 6 (3+3) RP Good Alive
43 57 7 174 pT3aN0 7 (4+3) RP Good Alive
66 69 780 41 pT2cNx 9 (4+5) AA Failed Deceased
n/a not applicable, AA androgen ablation, AS active surveillance RP radical prostatectomy, RT radiotherapy, WD 
waiting decision
Table 1 General features
PCa incidence 1.6%














Median PSA level at 
diagnosis





• The incidence of PCa in men with
renal grafts was 1.6%.
• Twenty-four patients (82.8%) were
diagnosed with prostatic biopsy
and five (17.2%) were detected
incidentally by transurethral
resection of prostate.
• The overall survival rates at 1, 5
and 10 years after PCa diagnosis
were 86.2%, 86.2% and 79.3%,
respectively.
• Only one patient died of PCa.
• Radical prostatectomy was
performed in 19 patients (65.5%)
and radiation therapy in 5 (17.2%).
